Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Angina Market

ID: MRFR/Pharma/4293-HCR
90 Pages
Vikita Thakur
Last Updated: April 24, 2026

Angina Market Research Report, by Type (Angina Pectoris), Diagnosis (Imaging, Stress Test), Treatment (Lifestyle, Medications, Angioplasty, and Stenting), End-Users (Hospital & Clinics, Diagnostic Centers, Academic Institutes)–Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Angina Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Type (USD Billion)
  49.     4.1.1 angina pectoris
  50.     4.1.2 unstable angina
  51.     4.1.3 prinzmetal angina
  52.     4.1.4 others
  53.   4.2 Healthcare, BY Diagnosis (USD Billion)
  54.     4.2.1 imaging
  55.     4.2.2 blood test
  56.     4.2.3 stress test
  57.     4.2.4 others
  58.   4.3 Healthcare, BY Treatment (USD Billion)
  59.     4.3.1 lifestyle changes
  60.     4.3.2 medications
  61.     4.3.3 angioplasty and stenting
  62.     4.3.4 coronary bypass surgery
  63.     4.3.5 others
  64.   4.4 Healthcare, BY End-User (USD Billion)
  65.     4.4.1 hospitals and clinics
  66.     4.4.2 diagnostic centers
  67.     4.4.3 academic institutes
  68.     4.4.4 others
  69.   4.5 Healthcare, BY Region (USD Billion)
  70.     4.5.1 North America
  71.       4.5.1.1 US
  72.       4.5.1.2 Canada
  73.     4.5.2 Europe
  74.       4.5.2.1 Germany
  75.       4.5.2.2 UK
  76.       4.5.2.3 France
  77.       4.5.2.4 Russia
  78.       4.5.2.5 Italy
  79.       4.5.2.6 Spain
  80.       4.5.2.7 Rest of Europe
  81.     4.5.3 APAC
  82.       4.5.3.1 China
  83.       4.5.3.2 India
  84.       4.5.3.3 Japan
  85.       4.5.3.4 South Korea
  86.       4.5.3.5 Malaysia
  87.       4.5.3.6 Thailand
  88.       4.5.3.7 Indonesia
  89.       4.5.3.8 Rest of APAC
  90.     4.5.4 South America
  91.       4.5.4.1 Brazil
  92.       4.5.4.2 Mexico
  93.       4.5.4.3 Argentina
  94.       4.5.4.4 Rest of South America
  95.     4.5.5 MEA
  96.       4.5.5.1 GCC Countries
  97.       4.5.5.2 South Africa
  98.       4.5.5.3 Rest of MEA
  99. 5 SECTION V: COMPETITIVE ANALYSIS
  100.   5.1 Competitive Landscape
  101.     5.1.1 Overview
  102.     5.1.2 Competitive Analysis
  103.     5.1.3 Market share Analysis
  104.     5.1.4 Major Growth Strategy in the Healthcare
  105.     5.1.5 Competitive Benchmarking
  106.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  107.     5.1.7 Key developments and growth strategies
  108.       5.1.7.1 New Product Launch/Service Deployment
  109.       5.1.7.2 Merger & Acquisitions
  110.       5.1.7.3 Joint Ventures
  111.     5.1.8 Major Players Financial Matrix
  112.       5.1.8.1 Sales and Operating Income
  113.       5.1.8.2 Major Players R&D Expenditure. 2023
  114.   5.2 Company Profiles
  115.     5.2.1 AstraZeneca (GB)
  116.       5.2.1.1 Financial Overview
  117.       5.2.1.2 Products Offered
  118.       5.2.1.3 Key Developments
  119.       5.2.1.4 SWOT Analysis
  120.       5.2.1.5 Key Strategies
  121.     5.2.2 Bristol-Myers Squibb (US)
  122.       5.2.2.1 Financial Overview
  123.       5.2.2.2 Products Offered
  124.       5.2.2.3 Key Developments
  125.       5.2.2.4 SWOT Analysis
  126.       5.2.2.5 Key Strategies
  127.     5.2.3 Novartis (CH)
  128.       5.2.3.1 Financial Overview
  129.       5.2.3.2 Products Offered
  130.       5.2.3.3 Key Developments
  131.       5.2.3.4 SWOT Analysis
  132.       5.2.3.5 Key Strategies
  133.     5.2.4 Pfizer (US)
  134.       5.2.4.1 Financial Overview
  135.       5.2.4.2 Products Offered
  136.       5.2.4.3 Key Developments
  137.       5.2.4.4 SWOT Analysis
  138.       5.2.4.5 Key Strategies
  139.     5.2.5 Sanofi (FR)
  140.       5.2.5.1 Financial Overview
  141.       5.2.5.2 Products Offered
  142.       5.2.5.3 Key Developments
  143.       5.2.5.4 SWOT Analysis
  144.       5.2.5.5 Key Strategies
  145.     5.2.6 Merck & Co. (US)
  146.       5.2.6.1 Financial Overview
  147.       5.2.6.2 Products Offered
  148.       5.2.6.3 Key Developments
  149.       5.2.6.4 SWOT Analysis
  150.       5.2.6.5 Key Strategies
  151.     5.2.7 GlaxoSmithKline (GB)
  152.       5.2.7.1 Financial Overview
  153.       5.2.7.2 Products Offered
  154.       5.2.7.3 Key Developments
  155.       5.2.7.4 SWOT Analysis
  156.       5.2.7.5 Key Strategies
  157.     5.2.8 Amgen (US)
  158.       5.2.8.1 Financial Overview
  159.       5.2.8.2 Products Offered
  160.       5.2.8.3 Key Developments
  161.       5.2.8.4 SWOT Analysis
  162.       5.2.8.5 Key Strategies
  163.     5.2.9 Bayer (DE)
  164.       5.2.9.1 Financial Overview
  165.       5.2.9.2 Products Offered
  166.       5.2.9.3 Key Developments
  167.       5.2.9.4 SWOT Analysis
  168.       5.2.9.5 Key Strategies
  169.   5.3 Appendix
  170.     5.3.1 References
  171.     5.3.2 Related Reports
  172. 6 LIST OF FIGURES
  173.   6.1 MARKET SYNOPSIS
  174.   6.2 NORTH AMERICA MARKET ANALYSIS
  175.   6.3 US MARKET ANALYSIS BY TYPE
  176.   6.4 US MARKET ANALYSIS BY DIAGNOSIS
  177.   6.5 US MARKET ANALYSIS BY TREATMENT
  178.   6.6 US MARKET ANALYSIS BY END-USER
  179.   6.7 CANADA MARKET ANALYSIS BY TYPE
  180.   6.8 CANADA MARKET ANALYSIS BY DIAGNOSIS
  181.   6.9 CANADA MARKET ANALYSIS BY TREATMENT
  182.   6.10 CANADA MARKET ANALYSIS BY END-USER
  183.   6.11 EUROPE MARKET ANALYSIS
  184.   6.12 GERMANY MARKET ANALYSIS BY TYPE
  185.   6.13 GERMANY MARKET ANALYSIS BY DIAGNOSIS
  186.   6.14 GERMANY MARKET ANALYSIS BY TREATMENT
  187.   6.15 GERMANY MARKET ANALYSIS BY END-USER
  188.   6.16 UK MARKET ANALYSIS BY TYPE
  189.   6.17 UK MARKET ANALYSIS BY DIAGNOSIS
  190.   6.18 UK MARKET ANALYSIS BY TREATMENT
  191.   6.19 UK MARKET ANALYSIS BY END-USER
  192.   6.20 FRANCE MARKET ANALYSIS BY TYPE
  193.   6.21 FRANCE MARKET ANALYSIS BY DIAGNOSIS
  194.   6.22 FRANCE MARKET ANALYSIS BY TREATMENT
  195.   6.23 FRANCE MARKET ANALYSIS BY END-USER
  196.   6.24 RUSSIA MARKET ANALYSIS BY TYPE
  197.   6.25 RUSSIA MARKET ANALYSIS BY DIAGNOSIS
  198.   6.26 RUSSIA MARKET ANALYSIS BY TREATMENT
  199.   6.27 RUSSIA MARKET ANALYSIS BY END-USER
  200.   6.28 ITALY MARKET ANALYSIS BY TYPE
  201.   6.29 ITALY MARKET ANALYSIS BY DIAGNOSIS
  202.   6.30 ITALY MARKET ANALYSIS BY TREATMENT
  203.   6.31 ITALY MARKET ANALYSIS BY END-USER
  204.   6.32 SPAIN MARKET ANALYSIS BY TYPE
  205.   6.33 SPAIN MARKET ANALYSIS BY DIAGNOSIS
  206.   6.34 SPAIN MARKET ANALYSIS BY TREATMENT
  207.   6.35 SPAIN MARKET ANALYSIS BY END-USER
  208.   6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
  209.   6.37 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS
  210.   6.38 REST OF EUROPE MARKET ANALYSIS BY TREATMENT
  211.   6.39 REST OF EUROPE MARKET ANALYSIS BY END-USER
  212.   6.40 APAC MARKET ANALYSIS
  213.   6.41 CHINA MARKET ANALYSIS BY TYPE
  214.   6.42 CHINA MARKET ANALYSIS BY DIAGNOSIS
  215.   6.43 CHINA MARKET ANALYSIS BY TREATMENT
  216.   6.44 CHINA MARKET ANALYSIS BY END-USER
  217.   6.45 INDIA MARKET ANALYSIS BY TYPE
  218.   6.46 INDIA MARKET ANALYSIS BY DIAGNOSIS
  219.   6.47 INDIA MARKET ANALYSIS BY TREATMENT
  220.   6.48 INDIA MARKET ANALYSIS BY END-USER
  221.   6.49 JAPAN MARKET ANALYSIS BY TYPE
  222.   6.50 JAPAN MARKET ANALYSIS BY DIAGNOSIS
  223.   6.51 JAPAN MARKET ANALYSIS BY TREATMENT
  224.   6.52 JAPAN MARKET ANALYSIS BY END-USER
  225.   6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
  226.   6.54 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS
  227.   6.55 SOUTH KOREA MARKET ANALYSIS BY TREATMENT
  228.   6.56 SOUTH KOREA MARKET ANALYSIS BY END-USER
  229.   6.57 MALAYSIA MARKET ANALYSIS BY TYPE
  230.   6.58 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS
  231.   6.59 MALAYSIA MARKET ANALYSIS BY TREATMENT
  232.   6.60 MALAYSIA MARKET ANALYSIS BY END-USER
  233.   6.61 THAILAND MARKET ANALYSIS BY TYPE
  234.   6.62 THAILAND MARKET ANALYSIS BY DIAGNOSIS
  235.   6.63 THAILAND MARKET ANALYSIS BY TREATMENT
  236.   6.64 THAILAND MARKET ANALYSIS BY END-USER
  237.   6.65 INDONESIA MARKET ANALYSIS BY TYPE
  238.   6.66 INDONESIA MARKET ANALYSIS BY DIAGNOSIS
  239.   6.67 INDONESIA MARKET ANALYSIS BY TREATMENT
  240.   6.68 INDONESIA MARKET ANALYSIS BY END-USER
  241.   6.69 REST OF APAC MARKET ANALYSIS BY TYPE
  242.   6.70 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS
  243.   6.71 REST OF APAC MARKET ANALYSIS BY TREATMENT
  244.   6.72 REST OF APAC MARKET ANALYSIS BY END-USER
  245.   6.73 SOUTH AMERICA MARKET ANALYSIS
  246.   6.74 BRAZIL MARKET ANALYSIS BY TYPE
  247.   6.75 BRAZIL MARKET ANALYSIS BY DIAGNOSIS
  248.   6.76 BRAZIL MARKET ANALYSIS BY TREATMENT
  249.   6.77 BRAZIL MARKET ANALYSIS BY END-USER
  250.   6.78 MEXICO MARKET ANALYSIS BY TYPE
  251.   6.79 MEXICO MARKET ANALYSIS BY DIAGNOSIS
  252.   6.80 MEXICO MARKET ANALYSIS BY TREATMENT
  253.   6.81 MEXICO MARKET ANALYSIS BY END-USER
  254.   6.82 ARGENTINA MARKET ANALYSIS BY TYPE
  255.   6.83 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS
  256.   6.84 ARGENTINA MARKET ANALYSIS BY TREATMENT
  257.   6.85 ARGENTINA MARKET ANALYSIS BY END-USER
  258.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
  259.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS
  260.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
  261.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER
  262.   6.90 MEA MARKET ANALYSIS
  263.   6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
  264.   6.92 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS
  265.   6.93 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT
  266.   6.94 GCC COUNTRIES MARKET ANALYSIS BY END-USER
  267.   6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
  268.   6.96 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS
  269.   6.97 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT
  270.   6.98 SOUTH AFRICA MARKET ANALYSIS BY END-USER
  271.   6.99 REST OF MEA MARKET ANALYSIS BY TYPE
  272.   6.100 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS
  273.   6.101 REST OF MEA MARKET ANALYSIS BY TREATMENT
  274.   6.102 REST OF MEA MARKET ANALYSIS BY END-USER
  275.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  276.   6.104 RESEARCH PROCESS OF MRFR
  277.   6.105 DRO ANALYSIS OF HEALTHCARE
  278.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  279.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  280.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  281.   6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
  282.   6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
  283.   6.111 HEALTHCARE, BY DIAGNOSIS, 2024 (% SHARE)
  284.   6.112 HEALTHCARE, BY DIAGNOSIS, 2024 TO 2035 (USD Billion)
  285.   6.113 HEALTHCARE, BY TREATMENT, 2024 (% SHARE)
  286.   6.114 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion)
  287.   6.115 HEALTHCARE, BY END-USER, 2024 (% SHARE)
  288.   6.116 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion)
  289.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  290. 7 LIST OF TABLES
  291.   7.1 LIST OF ASSUMPTIONS
  292.     7.1.1
  293.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  294.     7.2.1 BY TYPE, 2025-2035 (USD Billion)
  295.     7.2.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  296.     7.2.3 BY TREATMENT, 2025-2035 (USD Billion)
  297.     7.2.4 BY END-USER, 2025-2035 (USD Billion)
  298.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  299.     7.3.1 BY TYPE, 2025-2035 (USD Billion)
  300.     7.3.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  301.     7.3.3 BY TREATMENT, 2025-2035 (USD Billion)
  302.     7.3.4 BY END-USER, 2025-2035 (USD Billion)
  303.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  304.     7.4.1 BY TYPE, 2025-2035 (USD Billion)
  305.     7.4.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  306.     7.4.3 BY TREATMENT, 2025-2035 (USD Billion)
  307.     7.4.4 BY END-USER, 2025-2035 (USD Billion)
  308.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  309.     7.5.1 BY TYPE, 2025-2035 (USD Billion)
  310.     7.5.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  311.     7.5.3 BY TREATMENT, 2025-2035 (USD Billion)
  312.     7.5.4 BY END-USER, 2025-2035 (USD Billion)
  313.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  314.     7.6.1 BY TYPE, 2025-2035 (USD Billion)
  315.     7.6.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  316.     7.6.3 BY TREATMENT, 2025-2035 (USD Billion)
  317.     7.6.4 BY END-USER, 2025-2035 (USD Billion)
  318.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  319.     7.7.1 BY TYPE, 2025-2035 (USD Billion)
  320.     7.7.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  321.     7.7.3 BY TREATMENT, 2025-2035 (USD Billion)
  322.     7.7.4 BY END-USER, 2025-2035 (USD Billion)
  323.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  324.     7.8.1 BY TYPE, 2025-2035 (USD Billion)
  325.     7.8.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  326.     7.8.3 BY TREATMENT, 2025-2035 (USD Billion)
  327.     7.8.4 BY END-USER, 2025-2035 (USD Billion)
  328.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  329.     7.9.1 BY TYPE, 2025-2035 (USD Billion)
  330.     7.9.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  331.     7.9.3 BY TREATMENT, 2025-2035 (USD Billion)
  332.     7.9.4 BY END-USER, 2025-2035 (USD Billion)
  333.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  334.     7.10.1 BY TYPE, 2025-2035 (USD Billion)
  335.     7.10.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  336.     7.10.3 BY TREATMENT, 2025-2035 (USD Billion)
  337.     7.10.4 BY END-USER, 2025-2035 (USD Billion)
  338.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  339.     7.11.1 BY TYPE, 2025-2035 (USD Billion)
  340.     7.11.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  341.     7.11.3 BY TREATMENT, 2025-2035 (USD Billion)
  342.     7.11.4 BY END-USER, 2025-2035 (USD Billion)
  343.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  344.     7.12.1 BY TYPE, 2025-2035 (USD Billion)
  345.     7.12.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  346.     7.12.3 BY TREATMENT, 2025-2035 (USD Billion)
  347.     7.12.4 BY END-USER, 2025-2035 (USD Billion)
  348.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  349.     7.13.1 BY TYPE, 2025-2035 (USD Billion)
  350.     7.13.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  351.     7.13.3 BY TREATMENT, 2025-2035 (USD Billion)
  352.     7.13.4 BY END-USER, 2025-2035 (USD Billion)
  353.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  354.     7.14.1 BY TYPE, 2025-2035 (USD Billion)
  355.     7.14.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  356.     7.14.3 BY TREATMENT, 2025-2035 (USD Billion)
  357.     7.14.4 BY END-USER, 2025-2035 (USD Billion)
  358.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  359.     7.15.1 BY TYPE, 2025-2035 (USD Billion)
  360.     7.15.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  361.     7.15.3 BY TREATMENT, 2025-2035 (USD Billion)
  362.     7.15.4 BY END-USER, 2025-2035 (USD Billion)
  363.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  364.     7.16.1 BY TYPE, 2025-2035 (USD Billion)
  365.     7.16.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  366.     7.16.3 BY TREATMENT, 2025-2035 (USD Billion)
  367.     7.16.4 BY END-USER, 2025-2035 (USD Billion)
  368.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  369.     7.17.1 BY TYPE, 2025-2035 (USD Billion)
  370.     7.17.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  371.     7.17.3 BY TREATMENT, 2025-2035 (USD Billion)
  372.     7.17.4 BY END-USER, 2025-2035 (USD Billion)
  373.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  374.     7.18.1 BY TYPE, 2025-2035 (USD Billion)
  375.     7.18.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  376.     7.18.3 BY TREATMENT, 2025-2035 (USD Billion)
  377.     7.18.4 BY END-USER, 2025-2035 (USD Billion)
  378.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  379.     7.19.1 BY TYPE, 2025-2035 (USD Billion)
  380.     7.19.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  381.     7.19.3 BY TREATMENT, 2025-2035 (USD Billion)
  382.     7.19.4 BY END-USER, 2025-2035 (USD Billion)
  383.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  384.     7.20.1 BY TYPE, 2025-2035 (USD Billion)
  385.     7.20.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  386.     7.20.3 BY TREATMENT, 2025-2035 (USD Billion)
  387.     7.20.4 BY END-USER, 2025-2035 (USD Billion)
  388.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  389.     7.21.1 BY TYPE, 2025-2035 (USD Billion)
  390.     7.21.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  391.     7.21.3 BY TREATMENT, 2025-2035 (USD Billion)
  392.     7.21.4 BY END-USER, 2025-2035 (USD Billion)
  393.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  394.     7.22.1 BY TYPE, 2025-2035 (USD Billion)
  395.     7.22.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  396.     7.22.3 BY TREATMENT, 2025-2035 (USD Billion)
  397.     7.22.4 BY END-USER, 2025-2035 (USD Billion)
  398.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  399.     7.23.1 BY TYPE, 2025-2035 (USD Billion)
  400.     7.23.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  401.     7.23.3 BY TREATMENT, 2025-2035 (USD Billion)
  402.     7.23.4 BY END-USER, 2025-2035 (USD Billion)
  403.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  404.     7.24.1 BY TYPE, 2025-2035 (USD Billion)
  405.     7.24.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  406.     7.24.3 BY TREATMENT, 2025-2035 (USD Billion)
  407.     7.24.4 BY END-USER, 2025-2035 (USD Billion)
  408.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  409.     7.25.1 BY TYPE, 2025-2035 (USD Billion)
  410.     7.25.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  411.     7.25.3 BY TREATMENT, 2025-2035 (USD Billion)
  412.     7.25.4 BY END-USER, 2025-2035 (USD Billion)
  413.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  414.     7.26.1 BY TYPE, 2025-2035 (USD Billion)
  415.     7.26.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  416.     7.26.3 BY TREATMENT, 2025-2035 (USD Billion)
  417.     7.26.4 BY END-USER, 2025-2035 (USD Billion)
  418.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  419.     7.27.1 BY TYPE, 2025-2035 (USD Billion)
  420.     7.27.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  421.     7.27.3 BY TREATMENT, 2025-2035 (USD Billion)
  422.     7.27.4 BY END-USER, 2025-2035 (USD Billion)
  423.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  424.     7.28.1 BY TYPE, 2025-2035 (USD Billion)
  425.     7.28.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  426.     7.28.3 BY TREATMENT, 2025-2035 (USD Billion)
  427.     7.28.4 BY END-USER, 2025-2035 (USD Billion)
  428.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  429.     7.29.1 BY TYPE, 2025-2035 (USD Billion)
  430.     7.29.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  431.     7.29.3 BY TREATMENT, 2025-2035 (USD Billion)
  432.     7.29.4 BY END-USER, 2025-2035 (USD Billion)
  433.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  434.     7.30.1 BY TYPE, 2025-2035 (USD Billion)
  435.     7.30.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
  436.     7.30.3 BY TREATMENT, 2025-2035 (USD Billion)
  437.     7.30.4 BY END-USER, 2025-2035 (USD Billion)
  438.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  439.     7.31.1
  440.   7.32 ACQUISITION/PARTNERSHIP
  441.     7.32.1

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

  • angina pectoris
  • unstable angina
  • prinzmetal angina
  • others

Healthcare By Diagnosis (USD Billion, 2025-2035)

  • imaging
  • blood test
  • stress test
  • others

Healthcare By Treatment (USD Billion, 2025-2035)

  • lifestyle changes
  • medications
  • angioplasty and stenting
  • coronary bypass surgery
  • others

Healthcare By End-User (USD Billion, 2025-2035)

  • hospitals and clinics
  • diagnostic centers
  • academic institutes
  • others

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions